Correlation of Nrf2, NQO1, MRP1, cmyc and p53 in colorectal cancer and their relationships to clinicopathologic features and survival

International Journal of Clinical and Experimental Pathology

Volumn 7, Issue 3, 2014, Pages 1124-1131

  Ji, Lili ^a,b   Wei, Yingze ^a   Jiang, Tao ^c   Wang, Shuyang ^a  

^a FUDAN UNIVERSITY   (China)

^b NANTONG UNIVERSITY   (China)

^c UNIVERSITY OF ARIZONA   (United States)

Author keywords

Cmyc; Colorectal cancer (CRC); Multidrug resistant protein 1 (MRP1); NAD(P)H quinine oxidoreductase 1 (NQO1); NF E2 related factor 2 (Nrf2); P53

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1; NFE2L2 PROTEIN, HUMAN; NQO1 PROTEIN, HUMAN; PROTEIN P53; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); TP53 PROTEIN, HUMAN; TRANSCRIPTION FACTOR NRF2; TUMOR MARKER;

BIOSYNTHESIS; COLORECTAL TUMOR; HUMAN; IMMUNOHISTOCHEMISTRY; METABOLISM; MORTALITY; PROGNOSIS; SURVIVAL RATE;

COLORECTAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NAD(P)H DEHYDROGENASE (QUINONE); NF-E2-RELATED FACTOR 2; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84899548389     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Siegel R, Naishadham D and Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63: 11-30.
2. Furukawa M and Xiong Y. BTB protein Keap1 targets antioxidant transcription factor Nrf2 for ubiquitination by the Cullin 3-Roc1 ligase. Mol Cell Biol 2005; 25: 162-171.
3. Kensler TW, Wakabayashi N and Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 2007; 47: 89-116.
4. Lau A, Villeneuve NF, Sun Z, Wong PK and Zhang DD. Dual roles of Nrf2 in cancer. Pharmacol Res 2008; 58: 262-270.
5. Hayes JD and McMahon M. The double-edged sword of Nrf2: subversion of redox homeostasis during the evolution of cancer. Mol Cell 2006; 21: 732-734.
6. Kensler TW and Wakabayashi N. Nrf2: friend or foe for chemoprevention? Carcinogenesis 2010; 31: 90-99.
7. Homma S, Ishii Y, Morishima Y, Yamadori T, Matsuno Y, Haraguchi N, Kikuchi N, Satoh H, Sakamoto T, Hizawa N, Itoh K and Yamamoto M. Nrf2 enhances cell proliferation and resistance to anticancer drugs in human lung cancer. Clin Cancer Res 2009; 15: 3423-3432.
8. Kim SK, Yang JW, Kim MR, Roh SH, Kim HG, Lee KY, Jeong HG and Kang KW. Increased expression of Nrf2/ARE-dependent anti-oxidant proteins in tamoxifen-resistant breast cancer cells. Free Radic Biol Med 2008; 45: 537-546.
9. Cheung KL, Lee JH, Khor TO, Wu TY, Li GX, Chan J, Yang CS and Kong AN. Nrf2 knockout enhances intestinal tumorigenesis in Apc (min/+) mice due to attenuation of anti-oxidative stress pathway while potentiates inflammation. Mol Carcinog 2014 Jan; 53: 77-84.
10. Anwar-Mohamed A, Degenhardt OS, El Gendy MA, Seubert JM, Kleeberger SR and El-Kadi AO. The effect of Nrf2 knockout on the constitutive expression of drug metabolizing enzymes and transporters in C57Bl/6 mice livers. Toxicol In Vitro 2011; 25: 785-795.
11. Ji L, Li H, Gao P, Shang G, Zhang DD, Zhang N and Jiang T. Nrf2 pathway regulates multidrug-resistance-associated protein 1 in small cell lung cancer. PLoS One 2013; 8: e63404.
12. DeNicola GM, Karreth FA, Humpton TJ, Gopinathan A, Wei C, Frese K, Mangal D, Yu KH, Yeo CJ, Calhoun ES, Scrimieri F, Winter JM, Hruban RH, Iacobuzio-Donahue C, Kern SE, Blair IA and Tuveson DA. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature 2011; 475: 106-109.
13. Berg M, Danielsen SA, Ahlquist T, Merok MA, Agesen TH, Vatn MH, Mala T, Sjo OH, Bakka A, Moberg I, Fetveit T, Mathisen O, Husby A, Sandvik O, Nesbakken A, Thiis-Evensen E and Lothe RA. DNA sequence profiles of the colorectal cancer critical gene set KRAS-BRAF-PIK3CA-PTEN-TP53 related to age at disease onset. PLoS One 2010; 5: e13978.
14. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, Katoh Y, Oyake T, Hayashi N, Satoh K, Hatayama I, Yamamoto M and Nabeshima Y. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun 1997; 236: 313-322.
15. Favreau LV and Pickett CB. Transcriptional regulation of the rat NAD(P)H:quinone reductase gene. Identification of regulatory elements controlling basal level expression and inducible expression by planar aromatic compounds and phenolic antioxidants. J Biol Chem 1991; 266: 4556-4561.
16. Moinova HR and Mulcahy RT. An electrophile responsive element (EpRE) regulates beta-naphthoflavone induction of the human gamma-glutamylcysteine synthetase regulatory su-bunit gene. Constitutive expression is mediated by an adjacent AP-1 site. J Biol Chem 1998; 273: 14683-14689.
17. Alam J, Wicks C, Stewart D, Gong P, Touchard C, Otterbein S, Choi AM, Burow ME and Tou J. Mechanism of heme oxygenase-1 gene activation by cadmium in MCF-7 mammary epithelial cells. Role of p38 kinase and Nrf2 transcription factor. J Biol Chem 2000; 275: 27694-27702.
18. Zhang DD. Mechanistic studies of the Nrf2-Keap1 signaling pathway. Drug Metab Rev 2006; 38: 769-789.
19. Osburn WO and Kensler TW. Nrf2 signaling: an adaptive response pathway for protection against environmental toxic insults. Mutat Res 2008; 659: 31-39.
20. Hayes JD and McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 2009; 34: 176-188.
21. Ross D. Quinone reductases multitasking in the metabolic world. Drug Metab Rev 2004; 36: 639-654.
22. Siegel D, Gustafson DL, Dehn DL, Han JY, Boonchoong P, Berliner LJ and Ross D. NAD(P)H:quinone oxidoreductase 1: role as a superoxide scavenger. Mol Pharmacol 2004; 65: 1238-1247.
23. Siegel D, Bolton EM, Burr JA, Liebler DC and Ross D. The reduction of alpha-tocopherolquinone by human NAD(P)H: quinone oxidoreductase: the role of alpha-tocopherolhydroquinone as a cellular antioxidant. Mol Pharmacol 1997; 52: 300-305.
24. Cole SP, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AM and Deeley RG. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650-1654.
25. Borst P, Evers R, Kool M and Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J Natl Cancer Inst 2000; 92: 1295-1302.
26. Sablina AA, Budanov AV, Ilyinskaya GV, Agapova LS, Kravchenko JE and Chumakov PM. The antioxidant function of the p53 tumor suppressor. Nat Med 2005; 11: 1306-1313.